Adipocytokines in obesity and metabolic disease

    1. Haiming Cao
    1. National Heart, Lung and Blood Institute, National Institutes of Health, Center for Molecular Medicine, 10 Center Drive, Building 10, 8N109, MSC 1760, Bethesda, Maryland 20892, USA
    1. Correspondence should be addressed to H Cao; Email: haiming.cao{at}nih.gov

    Abstract

    The current global obesity pandemic is the leading cause for the soaring rates of metabolic diseases, especially diabetes, cardiovascular disease, hypertension, and non-alcoholic hepatosteatosis. Efforts devoted to find cures for obesity and associated disorders in the past two decades have prompted intensive interest in adipocyte biology, and have led to major advances in the mechanistic understanding of adipose tissue as an essential endocrine organ. Adipose tissue secretes an array of hormones (adipokines) that signal key organs to maintain metabolic homeostasis, and their dysfunction has been causally linked to a wide range of metabolic diseases. In addition, obesity induces production of inflammatory cytokines (often referred to together with adipokines as adipocytokines) and infiltration of immune cells into adipose tissue, which creates a state of chronic low-grade inflammation. Metabolic inflammation has been increasingly recognized as a unifying mechanism linking obesity to a broad spectrum of pathological conditions. This review focuses on classic examples of adipocytokines that have helped to form the basis of the endocrine and inflammatory roles of adipose tissue, and it also details a few newly characterized adipocytokines that provide fresh insights into adipose biology. Studies of adipocytokines in clinical settings and their therapeutic potential are also discussed.

    Keywords
    • Received in final form 30 October 2013
    • Accepted 7 November 2013
    • Made available online as an Accepted Preprint 8 January 2014
    | Table of Contents